Elicio Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

ELTX$1.61-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$7,006	$8,180	$14,784	$15,739
General and administrative	3,085	2,744	6,043	5,426
Total operating expenses	10,091	10,924	20,827	21,165
Loss from operations	(10,091)	(10,924)	(20,827)	(21,165)
Other (expense) income
Change in fair value of warrant liabilities	(859)	3,616	(1,366)	2,338
Loss on issuance of pre-funded warrants	—	—	—	(578)
Gain on sale of equipment	—	—	—	3
Foreign exchange transaction (loss) gain	—	(9)	—	144
Grant income	415	—	415	—
Interest income	168	137	378	287
Interest expense	(194)	(49)	(370)	(85)
Total other (expense) income, net	(470)	3,695	(943)	2,109
Net loss	(10,561)	(7,229)	(21,770)	(19,056)
Other comprehensive income (loss):
Foreign currency translation adjustment	74	32	105	(41)
Comprehensive loss	$(10,487)	$(7,197)	$(21,665)	$(19,097)
Net loss per common share, basic and diluted	$(0.66)	$(0.64)	$(1.50)	$(1.77)
Weighted average common shares and pre-funded warrants outstanding, basic and diluted	16,059,423	11,284,853	14,513,586	10,779,389

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.